# OnCo record paper-jupiter-02-toripalimab-chemotherapy-npc-nat-med-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-jupiter-02-toripalimab-chemotherapy-npc-nat-med-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-jupiter-02-toripalimab-chemotherapy-npc-nat-med-2021" ;
  schema:name "JUPITER-02: toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma"@en ;
  schema:description "Adding the PD-1 antibody toripalimab to gemcitabine and cisplatin lengthened the time before metastatic nasopharyngeal cancer progressed by about four months, and later improved survival, making chemo-immunotherapy the first-line standard."@en ;
  schema:url <https://onco.cc/key-papers/paper-jupiter-02-toripalimab-chemotherapy-npc-nat-med-2021/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/s41591-021-01444-0>, <https://pubmed.ncbi.nlm.nih.gov/34341578/> ;
  schema:sameAs <https://doi.org/10.1038/s41591-021-01444-0> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Mai HQ, Chen QY, Chen D, et al." ;
  onco:cancers <https://onco.cc/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/> ;
  onco:drugs <https://onco.cc/drugs/toripalimab/>, <https://onco.cc/drugs/gemcitabine-cisplatin/> ;
  onco:trials <https://onco.cc/trials/jupiter-02/> ;
  onco:journals <https://onco.cc/journals/nature-medicine/> .